ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
72 announcements with these filters
Sun Pharmaceutical Industries held its 34th Annual General Meeting, approving financial statements, director appointments, and a final dividend of Rs. 5 per share.
Sun Pharmaceutical informed the exchanges that its board meeting concluded on July 31, 2026, after adjourning for a break during the session.
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹15,300 Cr (+10.5% YoY) and net profit of ₹2,895 Cr (+27.0% YoY) for Q1 FY27.
Sun Pharma's partner, Philogen, has resubmitted the Marketing Authorization Application for Nidlegy to the European Medicines Agency for the treatment of melanoma.
Sun Pharma announced that Organon stockholders approved the proposed merger, moving the acquisition forward. The deal remains subject to remaining customary closing conditions.
Sun Pharma received SAHPRA approval to market generic semaglutide in South Africa. This marks the company's second market approval for the diabetes treatment after India.
Sun Pharmaceutical Industries scheduled a board meeting on July 31, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.
Sun Pharma reported FY26 sales of Rs 582 Bn with a 30.3% EBITDA margin. Strategy focuses on expanding the Global Innovative Medicines portfolio and maintaining leadership in the Indian market.
SUN PHARMA announces its 34th AGM on 31 Jul 2026 to adopt financials and declare ₹5/share dividend. Director reappointments and remuneration revisions are also on the agenda.
Sun Pharma has filed its Annual Report 2025-26 and Notice of 34th AGM. The report highlights global innovation and market leadership across key pharmaceutical segments.
Sun Pharma's independent director Mr. Gautam Doshi has been arrested in an unrelated matter. The company sees no impact on its operations or board.
Sun Pharmaceutical Industries scheduled its 34th AGM for July 31, 2026. The company fixed July 7, 2026, as the record date for a ₹5 per share dividend.
Sun Pharma reports Q4FY26 revenue growth of 13.6% and FY26 sales of INR 582 billion. Strategy focuses on Global Innovative Medicines and integrating the Organon acquisition.
Sun Pharmaceutical applied for reclassifying certain 'Promoter Group' shareholders into the 'Public' category. The regulatory move follows earlier internal company board intimations from May 2026.
Sun Pharma will present long-term follow-up data for UNLOXCYT at the ASCO 2026 meeting. The study shows durable responses and a manageable safety profile for laCSCC patients.
Sun Pharma delivered strong FY26 growth led by specialty medicines and India market share gains, despite US generic competition and regulatory headwinds.
Sun Pharma's board recommended a 500% final dividend for FY 2025-26. This move signals strong cash flows and a commitment to rewarding shareholders.
Sun Pharmaceutical's board approved promoter group reclassifications and adopted a revised Fair Disclosure Code. These administrative updates streamline regulatory compliance and internal governance frameworks.
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹14,612 Cr (+12.8% YoY) and net profit of ₹2,714 Cr (+26.2% YoY) for Q4 FY26.
Sun Pharma reported FY26 consolidated revenue of ₹58,220.11 Crore with a 11.9% growth. The board recommended a final dividend of ₹5 per share for the year.
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹14,612 Cr (+12.8% YoY) and net profit of ₹2,724 Cr (+26.1% YoY) for Q4 FY26.
Sun Pharma approved audited FY26 results and recommended a final dividend of Rs. 5 per share. Consolidated sales reached ₹58,462.04 Crore, marking 11.9% year-on-year growth.
Sun Pharma received requests from three promoter group members to reclassify 4,31,75,371 shares to the public category. The board will examine these requests in due course.
Sun Pharmaceutical appointed Dr. Andreas Eugen Busch as an Independent Director for five years. His extensive global R&D expertise will strengthen the board's drug discovery leadership.
Sun Pharmaceutical appointed Dr. Andreas Busch as Independent Director for five years. Ms. Rama Bijapurkar retires, and Ms. Satyavati Berera joins key committees.
Sun Pharmaceutical Industries scheduled a board meeting for May 22, 2026. The board will consider audited FY26 results and a final dividend recommendation.
Sun Pharmaceutical shareholders approved the appointment of Ms. Satyavati Berera as Independent Director via postal ballot. The five-year term is effective from May 08, 2026.
Sun Pharmaceutical Industries Limited announced that CRISIL and ICRA reaffirmed its 'AAA' and 'A1+' ratings. CRISIL placed the long-term rating on 'Watch with Developing Implications' following Sun Pharma's agreement to acquire Organon & Co.
Sun Pharma announced the acquisition of Organon & Company for an enterprise value of $11.75 billion (approx. ₹1,11,625 Crore). The deal expands Sun's footprint in women's health and biosimilars across 140 countries, including a significant entry into China. The transaction is expected to close in six to nine months and be EPS accretive from the first year.
Sun Pharma announces the acquisition of Organon & Company for $11.75bn Enterprise Value ($14/share), targeting leadership in women's health and a major expansion in China.